(UroToday.com) Dr. Stephen Williams, Urologist from the University of Texas Medical Branch in Galveston, presented “The Use of Psychotropic Drugs Among Bladder Cancer Patients in the United States.” Over 50% of bladder cancer patients have a new psychiatric diagnosis following bladder cancer treatment.
(UroToday.com) Dr. Laura Marandino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy presented “Cabozantinib plus durvalumab in patients with advanced urothelial carcinoma after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial.” As single agents, both durvalumab and cabozantinib have efficacy in advanced urothelial carcinoma.
(UroToday.com) Dr. Tetsutaro Hayashi, Hiroshima University Department of Urology, Hiroshima, Japan presented “Transition of ANX10 expression is a useful diagnostic and prognostic marker in upper tract urothelial carcinoma (UTUC).” There exists a relative paucity of informative biomarkers for UTUC compared to bladder urothelial carcinoma. Dr. Hayashi et al. investigated ANXA10 as a potential biomarker for […]
(UroToday.com) Celine Hardy, a Masters Student at Queen’s University, Kingston, Canada presented “Predictive and prognostic performance of IHC3 Immunohistochemistry-based molecular subtyping in muscle-invasive bladder cancer (MIBC).”
(UroToday.com) Dr. Nathan Brooks, Society of Urologic Oncology (SUO) Fellow at the MD Anderson Cancer Center, Houston, Texas, USA presented “Correlation Between Body Mass Index (BMI), diabetes mellitus (DM), and Outcomes in Patients Treated with Bacillus Calmette Guerin (BCG) Immunotherapy for non-muscle-invasive bladder cancer (NMIBC).” An ‘obesity paradox’ exists in a number of malignancies, characterized by generally […]
(UroToday.com) Dr. Wolfgang Beck, University of North Carolina, Chapel Hill, North Carolina, USA presented “Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma.” The investigators performed post hoc analysis on IMvigor210 data and identified an age cutoff point of 72 years, with older patients achieving a relatively better response than younger patients. […]
(UroToday.com) Dr. Hamed Ahmadi, Society of Urologic Oncology (SUO) Fellow at the University of Southern California, Los Angeles, California, USA presented “The Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumors: Data from Multi-institutional Registry.” While Blue Light cystoscopy (BLC) has a defined role in non-muscle-invasive bladder cancer (NMIBC), with increase detection and decreased recurrence […]
(UroToday.com) Dr. Bishoy Faltas, Weill Cornell Medicine, New York, NY, USA presented “Common Deleterious Germline Variants Shape the Urothelial Cancer Genome.” The authors performed whole-exome sequencing of matched bladder tumors and germline DNA.
(UroToday.com) Dr. Kelly Bree, Society of Urologic Oncology (SUO) Fellow at the MD Anderson Cancer Center, Houston, Texas presented “Impact of upper tract urothelial carcinoma (UTUC) on Outcomes of NMIBC Treated with Intravesical Bacillus Calmette Guerin (BCG) .” Little is known about the role of UTUC on contemporary intravesical BCG outcomes for non-muscle-invasive bladder cancer (NMIBC).
(UroToday.com) Dr. Raquel Benitez Dorta, Spanish National Cancer Research Centre, Madrid, Spain presented “Specific Genetic Susceptibility Patterns of the Urothelial bladder Cancer Taxonomic Subtypes.” Dr. Dorta et al. investigated an immunohistochemical phenotype in bladder tumors consisting of KRT14, FOXA1, and GATA3, and correlated expression of these markers with germline DNA variants.
